Compare TYRA & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | LNN |
|---|---|---|
| Founded | 2018 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 1988 |
| Metric | TYRA | LNN |
|---|---|---|
| Price | $30.11 | $124.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $34.80 | ★ $128.00 |
| AVG Volume (30 Days) | ★ 581.6K | 117.1K |
| Earning Date | 11-05-2025 | 01-08-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | N/A | ★ 8.56 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $665,905,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.91 |
| P/E Ratio | ★ N/A | $18.48 |
| Revenue Growth | N/A | ★ 8.81 |
| 52 Week Low | $6.42 | $106.10 |
| 52 Week High | $31.56 | $150.96 |
| Indicator | TYRA | LNN |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 54.48 |
| Support Level | $27.40 | $122.39 |
| Resistance Level | $31.56 | $127.13 |
| Average True Range (ATR) | 2.01 | 3.92 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 71.65 | 67.19 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.